Ipsen : Feedback IR Day et nouvelles guidances: expecting the worst but hoping for the best – Achat vs Neutre - OC: 124 €
>Nouvelles guidances : 3.2 Md€ de CA en 2022 et MOP >32% - Ipsen propose de nouvelles guidances et fixe des objectifs à horizon 2022 (3.2 Md€ de CA et MOp. à 32%). Celles-ci semblent conservatrices: i/ elles factorisent l'arrivée d'un générique d'octreotide et de lanreotide, respectivement, fin 2020 et fin 2021 (alors que le génériqueur Advanz a déjà essuyé 2 rejets de l’autorité finlandaise auprès de laquelle il a déposé sa demande d’AMM), ii/ ces perspectives repose...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.